$4.95
5.10% yesterday
Nasdaq, Dec 15, 10:00 pm CET
ISIN
CA03879J1003
Symbol
ABUS

Arbutus Biopharma Corporation Stock price

$4.95
+0.41 9.03% 1M
+1.37 38.27% 6M
+1.68 51.38% YTD
+1.40 39.44% 1Y
+2.24 82.66% 3Y
-0.02 0.40% 5Y
+0.39 8.55% 10Y
-2.27 31.42% 20Y
Nasdaq, Closing price Mon, Dec 15 2025
+0.24 5.10%
ISIN
CA03879J1003
Symbol
ABUS
Industry

Key metrics

Basic
Market capitalization
$905.9m
Enterprise Value
$812.2m
Net debt
positive
Cash
$93.7m
Shares outstanding
192.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
62.0 | 65.2
EV/Sales
55.6 | 58.4
EV/FCF
negative
P/B
11.7
Financial Health
Equity Ratio
73.9%
Return on Equity
-71.8%
ROCE
-36.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$14.6m | $13.9m
EBITDA
$-33.4m | -
EBIT
$-34.1m | $-40.4m
Net Income
$-42.3m | $-36.7m
Free Cash Flow
$-45.4m
Growth (TTM | estimate)
Revenue
116.8% | 125.3%
EBITDA
57.3% | -
EBIT
57.1% | 44.4%
Net Income
44.9% | 47.5%
Free Cash Flow
36.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-228.6% | -
EBIT
-233.3%
Net
-289.5% | -264.1%
Free Cash Flow
-310.5%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
8.3%
Employees
44
Rev per Employee
$140.0k
Show more

Is Arbutus Biopharma Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,086 stocks worldwide.

Arbutus Biopharma Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Arbutus Biopharma Corporation forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Arbutus Biopharma Corporation forecast:

Buy
89%
Hold
11%

Financial data from Arbutus Biopharma Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
15 15
117% 117%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
25% 25%
116%
- Research and Development Expense 29 29
54% 54%
199%
-33 -33
57% 57%
-229%
- Depreciation and Amortization 0.69 0.69
51% 51%
5%
EBIT (Operating Income) EBIT -34 -34
57% 57%
-233%
Net Profit -42 -42
45% 45%
-289%

In millions USD.

Don't miss a Thing! We will send you all news about Arbutus Biopharma Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arbutus Biopharma Corporation Stock News

Neutral
GlobeNewsWire
about one month ago
Strong financial position with cash, cash equivalents and marketable securities of $93.7M     Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling in Pfizer-BioNTech litigation issued in September 2025     Additional analysis of imdusiran (AB-729) clinical data shows: - 46% of Phase 2a patients met criteria to discontinue all treatment - 94% of long-term f...
Neutral
GlobeNewsWire
2 months ago
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused o...
Positive
The Motley Fool
4 months ago
Arbutus (ABUS) Q2 Revenue Surges 529%
More Arbutus Biopharma Corporation News

Company Profile

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Head office Canada
CEO Lindsay Androski
Employees 44
Founded 2005
Website www.arbutusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today